These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 8946776)

  • 1. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D; Spaas P; Specenier P
    Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT; McEwan AJ
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative radiotherapy in prostate cancer.
    Catton CN; Gospodarowicz MK
    Semin Urol Oncol; 1997 Feb; 15(1):65-72. PubMed ID: 9050141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy in the management of bone pain.
    Hoskin PJ
    Clin Orthop Relat Res; 1995 Mar; (312):105-19. PubMed ID: 7543390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT; Davis LP
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of strontium-89 systemic radiotherapy in the management of osseous metastases from prostate cancer.
    Soffen EM; Greenberg A; Baumann J; Corn BW
    Tech Urol; 1997; 3(2):76-80. PubMed ID: 9297766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
    Kiselev EN; Korytova LI; Karelin MI
    Vopr Onkol; 2005; 51(6):689-91. PubMed ID: 17037036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
    Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
    Di Lorenzo G; Autorino R; Ciardiello F; Raben D; Bianco C; Troiani T; Pizza C; De Laurentiis M; Pensabene M; D'Armiento M; Bianco AR; De Placido S
    Oncol Rep; 2003; 10(2):399-404. PubMed ID: 12579279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report.
    Mertens WC; Porter AT; Reid RH; Powe JE
    J Nucl Med; 1992 Aug; 33(8):1437-43. PubMed ID: 1634933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.